BioInfra Co., Ltd.
Financials
Valuation Metrics
BioInfra Co., Ltd.'s Market Cap is ₩84B. At end of 2025 it was ₩230B. Ranked #2426 of 2,436 in KR market (top 100%), #1642 of 1,649 on KOSDAQ (top 100%), #234 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 8.36B KRW | KR#2,426/2,436 Sec#234/234 |
| Revenue | 23.21B KRW | KR#2,100/2,436 Sec#149/234 |
| Net Income | -9.89B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 34.48B KRW | KR#2,300/2,436 Sec#215/234 |
| Net Assets | 12.54B KRW | KR#2,344/2,436 Sec#222/234 |
| Employees | 132 | KR#1,421/2,436 Sec#114/234 |
| Value | ||
| P/B | 0.67x | KR#1,105/2,436 Sec#59/234 |
| P/S | 0.36x | KR#711/2,436 Sec#18/234 |
| FCF Yield | -33.77% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -78.85% | KR#2,322/2,436 Sec#214/234 |
| ROA | -28.68% | KR#2,287/2,436 Sec#193/234 |
| Op. Margin | -27.92% | KR#2,171/2,436 Sec#151/234 |
| Revenue Growth | 1.08% | KR#1,369/2,436 Sec#126/234 |
| Financial Health | ||
| Debt Ratio | 274.97% | KR#2,072/2,436 Sec#216/234 |
| Total Debt | 12.70B KRW | KR#1,536/2,436 Sec#137/234 |
| FCF | -2.82B KRW | KR#1,382/2,436 Sec#106/234 |
| Cash | 2.96B KRW | KR#2,160/2,436 Sec#205/234 |
| Current Ratio | 0.59x | KR#2,197/2,436 Sec#209/234 |
| Dividend | ||
| Div. Yield | 17.86% | KR#6/2,436 Sec#1/234 |
| Div. Growth | -25.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -69.08% | KR#2,328/2,436 Sec#221/234 |
| 1M Return | -27.16% | KR#2,311/2,436 Sec#225/234 |
| From 52W High | -72.84% | KR#2,196/2,436 Sec#198/234 |
| 1Y MDD | -73.23% | KR#2,076/2,436 Sec#185/234 |
| Trading | ||
| Volume | 130,809 shares | KR#498/2,436 Sec#45/234 |
| Foreign Own. | 1.87% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -2,033 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,578 KRW | KR#1,892/2,436 Sec#150/234 |
Company Info
The company was established in 2007 as a Contract Research Organization (CRO) and listed on the KOSDAQ market in 2023 as a small and medium-sized venture company. Its main businesses include bioequivalence tests for generic medicines, Phase 1 clinical trials for incrementally modified drugs, clinical trials for regulatory approval, immunoanalysis, and pharmaceutical quality testing. The company holds six domestic and international patents in analysis technology and automation, including for tube opening/closing devices and dispensing systems in Korea, the U.S., and Japan. Bioinfra, founded in 2007, is headquartered in Gyeonggi-do, Yongin-si.